دورية أكاديمية
Aortic rupture following acute aortitis in a patient with head and neck carcinoma treated with nivolumab: a rare but severe immune-related adverse event.
| العنوان: | Aortic rupture following acute aortitis in a patient with head and neck carcinoma treated with nivolumab: a rare but severe immune-related adverse event. |
|---|---|
| المؤلفون: | Ohno Y; Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-ku, Niigata City, Niigata, 950-8510, Japan., Ueki Y; Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-ku, Niigata City, Niigata, 950-8510, Japan. ucuekin@gmail.com., Oshima S; Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-ku, Niigata City, Niigata, 950-8510, Japan., Omata J; Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-ku, Niigata City, Niigata, 950-8510, Japan., Yokoyama Y; Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-ku, Niigata City, Niigata, 950-8510, Japan., Takahashi T; Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-ku, Niigata City, Niigata, 950-8510, Japan., Shodo R; Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-ku, Niigata City, Niigata, 950-8510, Japan., Yamazaki K; Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-ku, Niigata City, Niigata, 950-8510, Japan., Horii A; Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-ku, Niigata City, Niigata, 950-8510, Japan. |
| المصدر: | European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery [Eur Arch Otorhinolaryngol] 2024 Apr; Vol. 281 (4), pp. 2037-2040. Date of Electronic Publication: 2024 Feb 03. |
| نوع المنشور: | Case Reports; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer International Country of Publication: Germany NLM ID: 9002937 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1434-4726 (Electronic) Linking ISSN: 09374477 NLM ISO Abbreviation: Eur Arch Otorhinolaryngol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Heidelberg : Springer International, c1990- |
| مواضيع طبية MeSH: | Aortitis*/chemically induced , Aortitis*/diagnostic imaging , Aortic Rupture*/chemically induced , Aortic Rupture*/diagnostic imaging , Aortic Rupture*/surgery , Carcinoma*, Humans ; Male ; Aged ; Nivolumab/adverse effects ; Tomography, X-Ray Computed |
| مستخلص: | Introduction: Immune-related adverse events (irAEs) due to immune checkpoint inhibitors may lead to discontinuation and treatment-related death. Acute aortitis is a rare but severe irAE. Case Presentation: A 67-year-old man with recurrent lower gingival carcinoma received nivolumab therapy. Twenty-three months later, he experienced chest compression, which resulted in syncope. Following a whole-body computed tomography (CT) scanning, which revealed diffuse thickening of the aorta, and systemic assessments of the causes of aortitis, he was diagnosed with acute aortitis due to irAE. Nivolumab discontinuation and oral steroids improved CT findings. However, 11 months after nivolumab discontinuation, he developed an aortic aneurysmal rupture. Endovascular aortic repair rescued him. A durable anti-cancer response was still observed 4 months after the aortic rupture. Conclusion: Although severe irAE, such as acute aortitis, occurred, the patient may still achieve a durable response. A broad examination and prompt treatment of irAE can help improve the patient's survival. (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.) |
| References: | Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867. https://doi.org/10.1056/NEJMoa1602252. (PMID: 10.1056/NEJMoa1602252277187845564292) Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212):1915–1928. https://doi.org/10.1016/S0140-6736(19)32591-7. (PMID: 10.1016/S0140-6736(19)32591-731679945) Ricciuti B, Genova C, De Giglio AD et al (2019) Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 145(2):479–485. https://doi.org/10.1007/s00432-018-2805-3. (PMID: 10.1007/s00432-018-2805-330506406) Freeman-Keller M, Kim Y, Cronin H et al (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22(4):886–894. https://doi.org/10.1158/1078-0432.CCR-15-1136. (PMID: 10.1158/1078-0432.CCR-15-113626446948) Ishihara H, Takagi T, Kondo T et al (2019) Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. Urol Oncol 37(6):355.e21-355.e29. https://doi.org/10.1016/j.urolonc.2019.03.003. (PMID: 10.1016/j.urolonc.2019.03.00330935847) Salem JE, Manouchehri A, Moey M et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19(12):1579–1589. https://doi.org/10.1016/S1470-2045(18)30608-9. (PMID: 10.1016/S1470-2045(18)30608-9304424976287923) Roy AK, Tathireddy HR, Roy M (2017) Aftermath of induced inflammation: acute periaortitis due to nivolumab therapy. BMJ Case Rep 2017:bcr2017221852. https://doi.org/10.1136/bcr-2017-221852. (PMID: 10.1136/bcr-2017-221852289424135747784) Henderson D, Eslamian G, Poon D et al (2020) Immune checkpoint inhibitor induced large vessel vasculitis. BMJ Case Rep 13(5):e233496. https://doi.org/10.1136/bcr-2019-233496. (PMID: 10.1136/bcr-2019-233496324303517239530) Mort J, Maheshwari S, Basu N et al (2022) A rare case of large-vessel vasculitis following checkpoint inhibitor therapy and pegfilgrastim. Case Rep Oncol Med 2022:7295305. https://doi.org/10.1155/2022/7295305. (PMID: 10.1155/2022/7295305352517258890883) Ninomiya R, Kinehara Y, Tobita S et al (2022) Inflammatory thoracic aortic aneurysm in a patient with advanced lung adenocarcinoma treated with pembrolizumab. Intern Med 61(15):2339–2341. https://doi.org/10.2169/internalmedicine.8688-21. (PMID: 10.2169/internalmedicine.8688-21350223509424081) Bloomer CH, Annabathula RV, Aggarwal V, Upadhya B, Lycan TW (2022) A case report of immune checkpoint inhibitor-induced aortitis treated with tocilizumab. Case Reports Immunol 2022:7971169. https://doi.org/10.1155/2022/7971169. (PMID: 10.1155/2022/7971169362774719581648) Gornik HL, Creager MA (2008) Aortitis. Circulation 117(23):3039–3051. https://doi.org/10.1161/CIRCULATIONAHA.107.760686. (PMID: 10.1161/CIRCULATIONAHA.107.760686185417542759760) Evans JM, O’Fallon WM, Hunder GG (1995) Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: a population-based study. Ann Intern Med 122(7):502–507. https://doi.org/10.7326/0003-4819-122-7-199504010-00004. (PMID: 10.7326/0003-4819-122-7-199504010-000047872584) Martini DJ, Hamieh L, McKay RR et al (2018) Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1/PD-L1 therapy for immune-related adverse events. Cancer Immunol Res 6(4):402–408. https://doi.org/10.1158/2326-6066.CIR-17-0220. (PMID: 10.1158/2326-6066.CIR-17-022029437040) Komiya K, Nakamura T, Abe T et al (2019) Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer. Thorac Cancer 10(9):1798–1804. https://doi.org/10.1111/1759-7714.13149. (PMID: 10.1111/1759-7714.13149313284166718019) Yasumatsu R, Matsuo M, Wakasaki T et al (2020) Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events. Acta Otolaryngol 140(12):1043–1048. https://doi.org/10.1080/00016489.2020.1807601. (PMID: 10.1080/00016489.2020.180760132808841) |
| فهرسة مساهمة: | Keywords: Acute aortitis; Aortic rupture; Head and neck carcinoma; Immune-related adverse event |
| المشرفين على المادة: | 31YO63LBSN (Nivolumab) |
| تواريخ الأحداث: | Date Created: 20240203 Date Completed: 20240318 Latest Revision: 20240402 |
| رمز التحديث: | 20240402 |
| DOI: | 10.1007/s00405-024-08495-2 |
| PMID: | 38308762 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder كن أول من يترك تعليقا!